JP2018524352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524352A5 JP2018524352A5 JP2017568376A JP2017568376A JP2018524352A5 JP 2018524352 A5 JP2018524352 A5 JP 2018524352A5 JP 2017568376 A JP2017568376 A JP 2017568376A JP 2017568376 A JP2017568376 A JP 2017568376A JP 2018524352 A5 JP2018524352 A5 JP 2018524352A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- complex according
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(NC(P(*)(O)=O)P(O)(O*)=O)=O Chemical compound *C(NC(P(*)(O)=O)P(O)(O*)=O)=O 0.000 description 5
- OUJRYYLEOPKIOL-ZANHISICSA-N OC(CN(CCN(CC(O)=O)Cc1cc(CCC(NC(P(O)(O)=O)P(O)(O)=O)=O)ccc1O)Cc(cc(CCC(NCCCCCC(NCCCC[C@@H](C(O)=O)NC(NC(C1)(C1C(O)=O)C(O)=O)=O)=O)=O)cc1)c1O)=O Chemical compound OC(CN(CCN(CC(O)=O)Cc1cc(CCC(NC(P(O)(O)=O)P(O)(O)=O)=O)ccc1O)Cc(cc(CCC(NCCCCCC(NCCCC[C@@H](C(O)=O)NC(NC(C1)(C1C(O)=O)C(O)=O)=O)=O)=O)cc1)c1O)=O OUJRYYLEOPKIOL-ZANHISICSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189652P | 2015-07-07 | 2015-07-07 | |
| US62/189,652 | 2015-07-07 | ||
| US201662320296P | 2016-04-08 | 2016-04-08 | |
| US62/320,296 | 2016-04-08 | ||
| PCT/US2016/041040 WO2017007790A1 (en) | 2015-07-07 | 2016-07-06 | Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524352A JP2018524352A (ja) | 2018-08-30 |
| JP2018524352A5 true JP2018524352A5 (https=) | 2019-07-25 |
| JP6792875B2 JP6792875B2 (ja) | 2020-12-02 |
Family
ID=57685907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568376A Active JP6792875B2 (ja) | 2015-07-07 | 2016-07-06 | Ｈｂｅｄ−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10253052B2 (https=) |
| EP (1) | EP3319643B1 (https=) |
| JP (1) | JP6792875B2 (https=) |
| KR (1) | KR102651945B1 (https=) |
| CN (1) | CN107847618B (https=) |
| AU (1) | AU2016289474C1 (https=) |
| DK (1) | DK3319643T3 (https=) |
| EA (1) | EA201890221A1 (https=) |
| IL (1) | IL256726A (https=) |
| MX (1) | MX377208B (https=) |
| WO (1) | WO2017007790A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107847618B (zh) | 2015-07-07 | 2021-07-16 | 五一一制药股份有限公司 | Hbed-二膦酸盐/酯、其放射金属轭合物和它们作为治疗诊断剂的用途 |
| TW201832750A (zh) * | 2017-03-02 | 2018-09-16 | 美商５１１製藥公司 | 放射性藥品標記裝置 |
| US11723992B2 (en) * | 2018-08-03 | 2023-08-15 | Board Of Regents, The University Of Texas System | Method for extraction and purification of 68GA |
| CN109438517B (zh) * | 2018-12-27 | 2021-01-08 | 北京久杰净化工程技术有限公司 | 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法 |
| CA3137963A1 (en) * | 2019-04-26 | 2020-10-29 | Five Eleven Pharma Inc. | Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents |
| WO2021067513A1 (en) * | 2019-10-01 | 2021-04-08 | City Of Hope | Metal chelating agents and methods of using the same |
| DE102021101216A1 (de) * | 2021-01-21 | 2022-07-21 | Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts | Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen |
| DE102022105175A1 (de) * | 2022-03-04 | 2023-09-07 | Atoms for Cure GmbH | Markierungsvorläufer und Radiotracer mit drei oder mehr Targeting-Vektoren für die nuklearmedizinische Theranostik |
| CN119060093B (zh) * | 2024-08-26 | 2025-09-05 | 广州医科大学附属第一医院（广州呼吸中心） | 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用 |
| CN119060094B (zh) * | 2024-08-26 | 2025-09-05 | 广州医科大学附属第一医院（广州呼吸中心） | 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003035114A1 (en) * | 2001-10-22 | 2003-05-01 | Dow Global Technologies Inc. | Radiopharmaceutical agent for the treatment of early stage cancer |
| KR20070087266A (ko) * | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| US7161000B2 (en) * | 2003-05-30 | 2007-01-09 | Sumitomo Chemical Company, Limited | Method for producing phenol condensate |
| US10925977B2 (en) * | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| CA2926573C (en) * | 2007-06-26 | 2018-08-28 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| US20120148492A1 (en) * | 2009-08-20 | 2012-06-14 | Fujifilm Ri Pharma Co., Ltd. | Bisphosphonic acid derivative and compound thereof labeled with radioactive metal nuclide |
| CN103459573B (zh) * | 2011-04-13 | 2015-11-25 | 弗门尼舍有限公司 | 用于控制加香醛和酮的释放的平衡动态混合物 |
| ITMI20121156A1 (it) | 2012-06-29 | 2013-12-30 | Consiglio Nazionale Ricerche | Metodo di elaborazione di immagini di tomografia a coerenza ottica |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CN107847618B (zh) | 2015-07-07 | 2021-07-16 | 五一一制药股份有限公司 | Hbed-二膦酸盐/酯、其放射金属轭合物和它们作为治疗诊断剂的用途 |
-
2016
- 2016-07-06 CN CN201680046397.5A patent/CN107847618B/zh active Active
- 2016-07-06 EA EA201890221A patent/EA201890221A1/ru unknown
- 2016-07-06 AU AU2016289474A patent/AU2016289474C1/en active Active
- 2016-07-06 US US15/203,602 patent/US10253052B2/en active Active
- 2016-07-06 KR KR1020187002872A patent/KR102651945B1/ko active Active
- 2016-07-06 MX MX2018000239A patent/MX377208B/es active IP Right Grant
- 2016-07-06 EP EP16821892.3A patent/EP3319643B1/en active Active
- 2016-07-06 JP JP2017568376A patent/JP6792875B2/ja active Active
- 2016-07-06 DK DK16821892.3T patent/DK3319643T3/da active
- 2016-07-06 WO PCT/US2016/041040 patent/WO2017007790A1/en not_active Ceased
-
2018
- 2018-01-03 IL IL256726A patent/IL256726A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524352A5 (https=) | ||
| Liu | Radiolabeled cyclic RGD peptide bioconjugates as radiotracers targeting multiple integrins | |
| EP3397968B1 (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| Ray Banerjee et al. | Effect of chelators on the pharmacokinetics of 99mTc-labeled imaging agents for the prostate-specific membrane antigen (PSMA) | |
| Edwards et al. | New and versatile ternary ligand system for technetium radiopharmaceuticals: water soluble phosphines and tricine as coligands in labeling a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with 99mTc | |
| Ray Banerjee et al. | Preclinical comparative study of 68Ga-labeled DOTA, NOTA, and HBED-CC chelated radiotracers for targeting PSMA | |
| JP6792875B2 (ja) | Ｈｂｅｄ−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用 | |
| Ferreira et al. | 68Ga small peptide imaging: comparison of NOTA and PCTA | |
| Isabel M. Prata | Gallium-68: a new trend in PET radiopharmacy | |
| Imberti et al. | Enhancing PET signal at target tissue in vivo: dendritic and multimeric tris (hydroxypyridinone) conjugates for molecular imaging of αvβ3 integrin expression with gallium-68 | |
| Maresca et al. | Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide | |
| CN109641924B (zh) | 作为检测前列腺特异性膜抗原的过表达的放射性药物的99mtc-edda/hynic-ipsma | |
| CZ20032564A3 (cs) | Značené antagonisty receptoru makrofágového lapače pro zobrazování atherosklerosy a citlivých plaků | |
| Chakraborty et al. | Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent | |
| Velikyan | Positron emitting [68Ga] Ga-based imaging agents: chemistry and diversity | |
| Singh et al. | Multivalent bifunctional chelator scaffolds for gallium-68 based positron emission tomography imaging probe design: signal amplification via multivalency | |
| Noor et al. | Bivalent inhibitors of prostate-specific membrane antigen conjugated to desferrioxamine B squaramide labeled with zirconium-89 or gallium-68 for diagnostic imaging of prostate cancer | |
| Zhao et al. | Synthesis and evaluation of 68Ga-and 177Lu-labeled (R)-vs (S)-DOTAGA prostate-specific membrane antigen-targeting derivatives | |
| Maresca et al. | Comprehensive radiolabeling, stability, and tissue distribution studies of technetium-99m single amino acid chelates (SAAC) | |
| Shi et al. | 2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics | |
| Gomez et al. | Synthesis and Evaluation of Diastereoisomers of 1, 4, 7-Triazacyclononane-1, 4, 7-tris-(glutaric acid)(NOTGA) for Multimeric Radiopharmaceuticals of Gallium | |
| Bhatt et al. | Phosphonate pendant armed propylene cross-bridged cyclam: synthesis and evaluation as a chelator for Cu-64 | |
| Badipa et al. | An overview of radiolabeled RGD peptides for theranostic applications | |
| Ferreira et al. | Pharmacokinetic modulation of radiolabeled chelates facilitated by phosphonate ester coordinating groups | |
| CN119751415B (zh) | 双靶向PSMA和FAP-α的前列腺癌诊断或治疗放射性药物 |